BioPharmSignal logoBioPharmSignal

Biotech News

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Corcept (CORT)CorceptEarnings

Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym ® and authorized generic product revenue of $208.6 million Lifyorli ™ product revenue of $47.6 million Increase in 2026 revenue guidance to $1.1 – $1.2 billion Net income of $43.0 million, compared to $35.1

Related news

CORTCorcept2026-07-22 20:05 EST

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-04-30 20:05 EST

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-04-29 20:05 EST

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-07-09 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

AMPHAmphastar Pharmaceuticals, Inc.2021-03-15 20:05 EST

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

AMPHAmphastar Pharmaceuticals, Inc.2020-07-30 20:05 EST

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020

View all latest news

Corcept

Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...

Recent company news

CORTCorcept2026-07-29 20:05 EST

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-07-22 20:05 EST

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-06-17 20:28 EST

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-06-06 20:45 EST

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

CORTCorcept2026-05-29 20:33 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Stock data

Close
107.95 USD
Market cap
7.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States